BidaskClub downgraded shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) from a buy rating to a hold rating in a research report sent to investors on Friday morning.

GWPH has been the topic of several other research reports. ValuEngine downgraded GW Pharmaceuticals PLC- from a strong-buy rating to a buy rating in a report on Wednesday, January 2nd. Cantor Fitzgerald cut their price target on GW Pharmaceuticals PLC- from $211.00 to $193.00 in a report on Sunday, December 9th. Piper Jaffray Companies reissued an overweight rating on shares of GW Pharmaceuticals PLC- in a report on Monday, November 5th. Morgan Stanley set a $227.00 price target on GW Pharmaceuticals PLC- and gave the stock a buy rating in a report on Thursday, October 11th. Finally, Leerink Swann assumed coverage on GW Pharmaceuticals PLC- in a report on Monday, November 12th. They issued an outperform rating and a $185.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of $176.56.

Shares of GWPH traded up $7.65 during mid-day trading on Friday, hitting $146.76. The stock had a trading volume of 770,198 shares, compared to its average volume of 438,387. The firm has a market cap of $4.43 billion, a price-to-earnings ratio of -13.90 and a beta of 2.79. The company has a current ratio of 6.66, a quick ratio of 6.34 and a debt-to-equity ratio of 0.01. GW Pharmaceuticals PLC- has a fifty-two week low of $90.14 and a fifty-two week high of $179.65.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last issued its earnings results on Tuesday, November 27th. The biopharmaceutical company reported ($2.76) EPS for the quarter, missing the consensus estimate of ($2.48) by ($0.28). The firm had revenue of $2.40 million during the quarter, compared to analyst estimates of $2.62 million. GW Pharmaceuticals PLC- had a negative return on equity of 50.93% and a negative net margin of 1,574.21%. GW Pharmaceuticals PLC-‘s revenue was down 4.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.14) EPS. On average, sell-side analysts predict that GW Pharmaceuticals PLC- will post -10.18 earnings per share for the current fiscal year.

In related news, CEO Justin D. Gover sold 22,620 shares of the firm’s stock in a transaction that occurred on Wednesday, January 2nd. The stock was sold at an average price of $8.33, for a total value of $188,424.60. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 5.50% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. New York State Common Retirement Fund raised its stake in GW Pharmaceuticals PLC- by 26.0% during the 4th quarter. New York State Common Retirement Fund now owns 8,378 shares of the biopharmaceutical company’s stock valued at $816,000 after acquiring an additional 1,730 shares in the last quarter. LPL Financial LLC raised its stake in GW Pharmaceuticals PLC- by 66.2% during the 4th quarter. LPL Financial LLC now owns 11,301 shares of the biopharmaceutical company’s stock valued at $1,101,000 after acquiring an additional 4,502 shares in the last quarter. GW&K Investment Management LLC bought a new stake in GW Pharmaceuticals PLC- during the 4th quarter valued at $2,980,000. Jennison Associates LLC raised its stake in GW Pharmaceuticals PLC- by 39.2% during the 4th quarter. Jennison Associates LLC now owns 515,281 shares of the biopharmaceutical company’s stock valued at $50,183,000 after acquiring an additional 145,227 shares in the last quarter. Finally, Canada Pension Plan Investment Board raised its stake in GW Pharmaceuticals PLC- by 327.3% during the 4th quarter. Canada Pension Plan Investment Board now owns 1,175,000 shares of the biopharmaceutical company’s stock valued at $114,424,000 after acquiring an additional 900,000 shares in the last quarter. 69.19% of the stock is currently owned by institutional investors and hedge funds.

GW Pharmaceuticals PLC- Company Profile

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

Recommended Story: How to Invest in a Bull Market

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.